GlaxoSmithKline Stock Forum

» 15+ upcoming FDA decisions to watch: 👀 👇
$GlaxoSmithKline(GSK.US)$ : Arexvy
$Genfit(GNFT.US)$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US)$ : Elafibranor
$Eli Lilly and Co(LLY.US)$ : Donanemab - AdCom meeting 🗓️
$Regeneron Pharmaceuticals(REGN.US)$ : Kevzara (sarilumab)
$Bristol-Myers Squibb(BMY.US)$ : Augtyro™ (Repotrectinib)
$Geron(GERN.US)$ : Imetelstat
$Merck & Co(MRK.US)$ : V116
$Amgen(AMGN.US)$ : BLINCYTO (blinatumomab)
$Sarepta Therapeutics(SRPT.US)$ : ELEVIDYS
$Merck & Co(MRK.US)$ : KEYTRUDA ...

$GlaxoSmithKline(GSK.US)$  do you guys think the fda case will be approved tomorrow? the company has had positive clinical trials.

See remaining FDA PDUFAs in May 👀👇
$Bristol-Myers Squibb(BMY.US)$ : Breyanzi
‣ PDUFA date: 5/31/24 (sBLA)
$Moderna(MRNA.US)$ : mRNA-1345
‣ PDUFA date: End of May 2024 (est.) (BLA)
📣 Buckle up & get ready for next month...
June brings 17 PDUFA decisions: 🔥 🔥
$Catalyst Pharmaceuticals(CPRX.US)$ : FIRDAPSE® (Amifampridine)
$GlaxoSmithKline(GSK.US)$ : Arexvy
$Genfit(GNFT.US)$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US)$ : Elafibranor
$Regeneron Pharmaceuticals(REGN.US)$ : Kevzara (sarilumab)
$Bristol-Myers Squibb(BMY.US)$ : Augtyro...

Top 10 drug companies raked in NEARLY TRIPLE the revenue in 2023 ($491B) vs 2013 ($165B) 2013 vs. 2023.
$AbbVie(ABBV.US)$ +189%
$Bristol-Myers Squibb(BMY.US)$ +175%
$Johnson & Johnson(JNJ.US)$ +95%
$AstraZeneca(AZN.US)$ +78%
$NVM +45%
$Merck & Co(MRK.US)$ +37% 
$ROCHE HOLDING AG(RHHBY.US)$ +27%
$Pfizer(PFE.US)$ +13%
$GlaxoSmithKline(GSK.US)$ +13%
----- $SPDR S&P 500 ETF(SPY.US)$ +12% -----
$Sanofi(SNY.US)$ +3%
Source: Arjun Murthy on the HR app!

A look at one of the major acquisition deals YTD…👇
$MRTX
Acquired By: Bristol-Myers Squibb $Bristol-Myers Squibb(BMY.US)$
Date: Jan. 23, 2024
Price: $4.8B
$AbbVie(ABBV.US)$ $GlaxoSmithKline(GSK.US)$

$GlaxoSmithKline(GSK.US)$ One day up, next 3-4 days will go down again